Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acellular pertussis vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The acellular pertussis vaccine is an inactivated subunit vaccine designed to protect against whooping cough (pertussis), caused by the bacterium Bordetella pertussis. Unlike whole-cell vaccines that use killed bacteria, the acellular version contains purified components of the bacterium—typically three to five proteins such as inactivated pertussis toxin (PT), filamentous hemagglutinin (FHA), fimbrial antigens (Fim2 and Fim3), and pertactin. These antigens stimulate an immune response without exposing recipients to the full range of side effects seen with whole-cell vaccines. The mechanism of action involves inducing immunity by generating antibodies against these key virulence factors of B. pertussis. Acellular formulations are almost always given in combination with diphtheria and tetanus toxoids as part of DTaP or Tdap vaccines for children and adults[1][4][5]. The primary indication is prevention of whooping cough; it is also used in combination products for broader immunization schedules.
- Brand names
- InfanrixDaptacelBoostrixAdacelTripediaACEL-IMUNE
- Other names
- aP vaccine
02
Targets
FHA (Filamentous hemagglutinin)FIM2/FIM3 (Fimbriae types 2 and 3)PRN (Pertactin)
Beyond the preview
Go deeper on acellular pertussis vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acellular pertussis vaccine.